title: Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates.
abstract: We report safety and tolerability of raltegravir (RAL) as a forth HIV agent in two highly viraemic newborns. Raltegravir (6 mg/kg) was given orally twice daily. The other antiretrovirals were assumed according to standard dose for newborns. The first baby was born at week 36. An antiretroviral therapy consisting of zidovudine, lamivudine, and lopinavir/ritonavir was started 96 hour after delivery. Raltegravir was added at hour 120, being plasma HIV-1 RNA above 10×10(6) copies/ml. HIV RNA declined to 5·000 copies/ml at day 30. The second baby was born at week 40. He was started on zidovudine, lamivudine, and nevirapine at day 0, while RAL was added at day 3. Plasma HIV-1 RNA declined from 6·6×10(6) at birth to 52 copies/ml at day 28. RAL tolerability was good in both patients, one with gamma-glutamyltransferase increase, which normalized after RAL discontinuation. Raltegravir-based four drug regimen may be effective and well tolerated in highly viraemic HIV neonates up to 4 weeks.
authors.affiliation: a Infectious Diseases Unit, AO Papa Giovanni XXIII , Bergamo , Italy.
authors.forename: Diego
authors.initials: D
authors.lastname: Ripamonti
authors.affiliation: b Infectious Diseases Unit, University of Genoa, IRCCS San Martino , IST Genoa , Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Tatarelli
authors.affiliation: a Infectious Diseases Unit, AO Papa Giovanni XXIII , Bergamo , Italy.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Mangili
authors.affiliation: b Infectious Diseases Unit, University of Genoa, IRCCS San Martino , IST Genoa , Italy.
authors.forename: Cristina
authors.initials: C
authors.lastname: Gotta
authors.affiliation: a Infectious Diseases Unit, AO Papa Giovanni XXIII , Bergamo , Italy.
authors.forename: Simone V
authors.initials: SV
authors.lastname: Benatti
authors.affiliation: b Infectious Diseases Unit, University of Genoa, IRCCS San Martino , IST Genoa , Italy.
authors.forename: Bianca
authors.initials: B
authors.lastname: Bruzzone
authors.affiliation: a Infectious Diseases Unit, AO Papa Giovanni XXIII , Bergamo , Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Callegaro
authors.affiliation: b Infectious Diseases Unit, University of Genoa, IRCCS San Martino , IST Genoa , Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Viscoli
authors.affiliation: a Infectious Diseases Unit, AO Papa Giovanni XXIII , Bergamo , Italy.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Ruggeri
authors.affiliation: b Infectious Diseases Unit, University of Genoa, IRCCS San Martino , IST Genoa , Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Di Biagio
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D019428:HIV Integrase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D008297:Male; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D000068898:Raltegravir Potassium / Q000627:therapeutic use*; D014766:Viremia / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D019428:HIV Integrase Inhibitors; D000068898:Raltegravir Potassium
keywords: Antiretroviral; HAART; HIV-infected children; Infants; Raltegravir